AZ “79% effective in large-scale clinical trials in the United States…no blood clots appear”
[뉴스리뷰]
[앵커]
AstraZeneca, a pharmaceutical company, announced that a large-scale vaccine clinical trial conducted in the United States showed 79% effectiveness.
It is significantly higher than the existing clinical effect of 70.4%.
Above all, he stressed that it has been shown to not increase the risk of forming blood clots.
Reporter Yoon Seok-i.
[기자]
AstraZeneca announced that it was 79% effective in a large-scale phase 3 clinical trial conducted in the United States.
It is considerably higher than the 70.4% announced at the end of last year, but is still lower than the 95% Pfizer vaccine and 94.5% Modena vaccine.
AstraZeneca explained that it was 80% effective, slightly higher than the overall average, for seniors aged 65 and over, and 100% effective in preventing progression to a severe condition requiring hospitalization.
The vaccine was also effective at all ages, including the elderly, and did not appear to increase the risk of blood clots in particular.
About 32,000 people participated in this US clinical trial.
Of these, about 20,000 were vaccinated, and the rest were compared with fake drugs.
The University of Oxford, UK, which jointly developed the COVID-19 vaccine with AstraZeneca, also announced that the vaccine was safe and highly effective in phase 3 clinical trials conducted in the United States, Chile, and Peru for all age groups.
There is hope in the medical community that the new clinical results could end the confusion surrounding the effectiveness of the AstraZeneca vaccine.
Based on the results of this clinical trial, AstraZeneca said it will create and submit data for emergency use approval in the United States in the near future.
This is Yonhap News TV.
Yonhap News TV article inquiries and reports: katok/line jebo23
(End)